Transforming growth factor-beta1 in supernatants from stored red blood cells inhibits neutrophil locomotion. 2003

Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
Department of Internal Medicine and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Italy.

Studies comparing transfusion and nontransfusion patients suggest an increased risk of postoperative infections in transfusion groups. Supernatants of blood components have been shown to affect the function of T lymphocytes and natural killer cells. Here, we found that supernatants from stored red blood cells (RBCs) inhibit human neutrophil migration in response to formyl peptides and stimulate neutrophil locomotion. These effects can be observed with high dilutions of RBC supernatants, such as 1:5 x 106 (vol/vol), able to trigger locomotion as well as desensitization of the cells to alternative chemoattractants. The phenomenon might be mediated by chemoattractants present in the supernatants. As RBC supernatants failed to mobilize intracellular free calcium, the chemoattractants should belong to the group of pure chemoattractants, that is, soluble Fas ligand (sFasL) and transforming growth factor-beta1 (TGF-beta1), known to act without increasing calcium levels. Recombinant TGF-beta1, but not sFasL, was found to reproduce the ability of RBC supernatants to both inhibit neutrophil response to formyl peptides and stimulate neutrophil locomotion. Moreover, TGF-beta1-immunodepleted supernatants did not display neutrophil-directed activities. Finally, RBC supernatants from RBCs stored after depletion of leukocytes were incapable of affecting neutrophil function. With neutrophils acting as a first-line antimicrobial defense, the ability, shown here, of high dilutions of RBC supernatants to inhibit neutrophil chemotaxis through TGF-beta1 may be a relevant determinant of infections in the postoperative period for transfusion patients. Consistently, the neutrophil chemotactic response to formyl peptide was inhibited by the plasma obtained from 5 transfusion patients.

UI MeSH Term Description Entries
D009240 N-Formylmethionine Leucyl-Phenylalanine A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated. F-Met-Leu-Phe,N-Formyl-Methionyl-Leucyl-Phenylalanine,Formylmet-Leu-Phe,Formylmethionyl Peptide,Formylmethionyl-Leucyl-Phenylalanine,Formylmethionylleucylphenylalanine,N-Formylated Peptide,N-formylmethionyl-leucyl-phenylalanine,fMet-Leu-Phe,F Met Leu Phe,Formylmet Leu Phe,Formylmethionyl Leucyl Phenylalanine,Leucyl-Phenylalanine, N-Formylmethionine,N Formyl Methionyl Leucyl Phenylalanine,N Formylated Peptide,N Formylmethionine Leucyl Phenylalanine,N formylmethionyl leucyl phenylalanine,Peptide, Formylmethionyl,Peptide, N-Formylated,fMet Leu Phe
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D001793 Blood Preservation The process by which blood or its components are kept viable outside of the organism from which they are derived (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism). Blood Preservations,Preservation, Blood,Preservations, Blood
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016212 Transforming Growth Factor beta A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins. Bone-Derived Transforming Growth Factor,Platelet Transforming Growth Factor,TGF-beta,Milk Growth Factor,TGFbeta,Bone Derived Transforming Growth Factor,Factor, Milk Growth,Growth Factor, Milk
D053773 Transforming Growth Factor beta1 A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME. TGF-beta1,Transforming Growth Factor-beta1,TGF-beta-1,TGF-beta1 Latency-Associated Protein,TGF-beta1LAP,Transforming Growth Factor beta 1 Latency Associated Peptide,Transforming Growth Factor beta I,Latency-Associated Protein, TGF-beta1,TGF beta 1,TGF beta1 Latency Associated Protein,TGF beta1LAP
D018375 Neutrophil Activation The process in which the neutrophil is stimulated by diverse substances, resulting in degranulation and/or generation of reactive oxygen products, and culminating in the destruction of invading pathogens. The stimulatory substances, including opsonized particles, immune complexes, and chemotactic factors, bind to specific cell-surface receptors on the neutrophil. Activation, Neutrophil,Activations, Neutrophil,Neutrophil Activations
D039481 CD11b Antigen A CD antigen that contains a conserved integrin I-domain which is involved in ligand binding. When combined with CD18 the two subunits form MACROPHAGE-1 ANTIGEN. Antigens, CD11b,CD11b Antigens,Integrin alphaM,Mo1 Antigen,Complement Component Receptor 3, alpha,ITGAM Protein,Integrin alpha M,Mo1 Glycoprotein,alphaM Integrin,Antigen, CD11b,Antigen, Mo1,Integrin, alphaM,alpha M, Integrin,alphaM, Integrin

Related Publications

Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
April 2002, Molecular human reproduction,
Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
February 2004, Cytokine,
Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
July 1997, Molecular and cellular endocrinology,
Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
December 2000, Naunyn-Schmiedeberg's archives of pharmacology,
Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
June 1996, Proceedings of the National Academy of Sciences of the United States of America,
Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
July 2007, Clinical and experimental immunology,
Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
November 1999, DNA and cell biology,
Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
June 2009, Reproduction (Cambridge, England),
Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
March 2003, Chinese medical journal,
Massimo Ghio, and Luciano Ottonello, and Paola Contini, and Massimo Amelotti, and Clemente Mazzei, and Francesco Indiveri, and Francesco Puppo, and Franco Dallegri
October 1999, FEBS letters,
Copied contents to your clipboard!